Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101468102 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1755-3768 (Electronic) Linking ISSN: 1755375X NLM ISO Abbreviation: Acta Ophthalmol Subsets: MEDLINE
    • بيانات النشر:
      Publication: Oxford, UK : Wiley-Blackwell
      Original Publication: Oxford, UK ; Malden, MA : Blackwell Munksgaard
    • الموضوع:
      Glatiramer Acetate/*therapeutic use ; Glaucoma, Angle-Closure/*drug therapy ; Intraocular Pressure/*physiology ; Neuroprotective Agents/*therapeutic use ; Visual Fields/*physiology; Acute Disease ; Disease Progression ; Double-Blind Method ; Female ; Glaucoma, Angle-Closure/diagnosis ; Glaucoma, Angle-Closure/physiopathology ; Humans ; Male ; Middle Aged ; Retinal Ganglion Cells/pathology ; Tomography, Optical Coherence ; Treatment Outcome ; Visual Fields/drug effects
    • نبذة مختصرة :
      Purpose: To investigate the neuroprotective effect of Copolymer-1 (Cop-1) in patients with acute primary angle closure (APAC) in a randomized double-masked controlled trial.
      Methods: After initial medical management, APAC patients were randomized to receive either subcutaneous Cop-1 or placebo within 24 hr and at 1 week. After laser peripheral iridotomy (LPI), subjects underwent serial visual field (VF) tests and retinal nerve fibre layer (RNFL) thickness measurements with spectral-domain optical coherence tomography. The primary outcome measure was mean number of progressing points (significant slope of ≥ 1 dB per year sensitivity loss) over 16 weeks based on pointwise linear regression analysis, and the secondary outcome measure was the change in RNFL thickness.
      Results: Thirty-eight patients (19 in each group) completed the study. Twenty-five (65.8%) were female, the majority being Chinese (86.8%) with mean age 62.5 years (SD 8.1). Patients in the Cop-1 group were found to have mean of 0.32 (SD 0.95) progressing points compared to 2.74 (SD 5.31) in the placebo group (p = 0.09), while 3/19 (15.8%) of Cop-1 treated patients had 1 or more progressing points compared to 7/19 (36.8%) in the placebo group (p = 0.14). There was no difference in change of RNFL thickness between groups (p = 0.57). We found improvement of mean deviation (MD) at week 16 in the Cop-1 group (p = 0.01) compared to worsening of MD in the placebo group (p = 0.04).
      Conclusion: After APAC, there was no difference in VF progression (or RNFL thickness change) between Cop-1 and placebo groups. However, there was improvement of MD in Cop-1 treated patients.
      (© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.)
    • Grant Information:
      NMRC/CSA/004/2008 National Medical Research Council; NMRC/TCR/002-SERI/2008 National Medical Research Council
    • Contributed Indexing:
      Keywords: acute primary angle closure; copaxone; neuroprotection; randomized controlled trial
    • الرقم المعرف:
      0 (Neuroprotective Agents)
      5M691HL4BO (Glatiramer Acetate)
    • الموضوع:
      Date Created: 20190328 Date Completed: 20190903 Latest Revision: 20190903
    • الموضوع:
      20231215
    • الرقم المعرف:
      10.1111/aos.14099
    • الرقم المعرف:
      30916898